Regulatory Momentum Strong FDA-registered status for the CelTivity Biopsy Assessment System and recent leadership appointment signal ongoing regulatory and strategic momentum, presenting a near-term opportunity to upsell to clinical sites seeking validated, compliant intraprocedural diagnostic tools.

Clinical Differentiation Real-time metabolic imaging that preserves tissue integrity offers a unique value proposition versus traditional ROSE and histology, making it a compelling pilot or expansion option for bronchoscopic teams aiming to improve diagnostic yield and reduce indeterminate biopsies.

Workflow Fit Designed to integrate with existing bronchoscopy workflows without tissue disruption, enabling hospitals to deploy without major procedural changes, which lowers adoption risk and accelerates deployment in target centers.

Evidence Opportunity Clinically validated claims around faster procedures and increased diagnostic confidence create a compelling case for clinical studies, advocacy from early adopters, and expansion into centers focusing on precision oncology and molecular diagnostics.

Growth Signals Current revenue scale and modest funding indicate a lean, growing company with room for expanded commercial coverage, partner ecosystems, and portfolio expansion into adjacent diagnostic markets—ideal for strategic partnerships or channel partnerships with larger medtech players.